<DOC>
	<DOCNO>NCT02399137</DOCNO>
	<brief_summary>The purpose study determine whether combination MM-141 plus nab-paclitaxel gemcitabine effective nab-paclitaxel gemcitabine alone base Progression Free Survival ( PFS ) front-line metastatic pancreatic cancer patient high serum level free IGF-1 .</brief_summary>
	<brief_title>A Phase 2 Study MM-141 Plus Nab-paclitaxel Gemcitabine Front-line Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled Phase 2 study MM-141 plus nab-paclitaxel gemcitabine placebo plus nab-paclitaxel gemcitabine front-line metastatic pancreatic cancer . All patient initially screen free IGF-1 status . Eligible patient high free IGF-1 randomize receive MM-141 plus nab-paclitaxel gemcitabine placebo plus nab-paclitaxel gemcitabine patient . Patients low free IGF-1 patient high free IGF-1 otherwise eligible follow observational group .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Metastatic adenocarcinoma pancreas . Patients islet cell neoplasm eligible . Patient must receive prior radiotherapy , surgery , chemotherapy , investigational therapy treatment metastatic disease . Blood sample send free IGF1 test ECOG performance status ( PS ) 0 1 Patients present localized disease Patients CNS malignancy ( primary metastatic ) Clinically significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Front-line Pancreatic Cancer</keyword>
	<keyword>Metastatic Pancreatic Cancer</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Free IGF-1</keyword>
	<keyword>Heregulin</keyword>
</DOC>